CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 192 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246 | +2.1% | 21,074 | +17.1% | 0.00% | – |
| Q2 2023 | $241 | -37.2% | 17,996 | -22.4% | 0.00% | -100.0% |
| Q1 2023 | $384 | -48.5% | 23,178 | -42.3% | 0.00% | 0.0% |
| Q4 2022 | $746 | -99.7% | 40,158 | +73.6% | 0.00% | – |
| Q3 2022 | $296,000 | +86.2% | 23,126 | +1.8% | 0.00% | – |
| Q2 2022 | $159,000 | -72.7% | 22,708 | -67.7% | 0.00% | -100.0% |
| Q1 2022 | $582,000 | +1087.8% | 70,275 | +853.0% | 0.00% | – |
| Q4 2021 | $49,000 | +6.5% | 7,374 | -16.3% | 0.00% | – |
| Q3 2021 | $46,000 | -53.5% | 8,815 | -59.2% | 0.00% | – |
| Q1 2021 | $99,000 | +86.8% | 21,583 | +18.8% | 0.00% | – |
| Q3 2020 | $53,000 | +1.9% | 18,161 | +59.7% | 0.00% | – |
| Q2 2020 | $52,000 | +6.1% | 11,370 | -10.7% | 0.00% | – |
| Q1 2020 | $49,000 | +250.0% | 12,730 | +237.7% | 0.00% | – |
| Q4 2019 | $14,000 | – | 3,770 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |